In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

Conclusions: With the development of recombinant DNA techniques, it has become possible to develop new biologic therapies that can be designed to specifically alter physiological responses. These new ...

Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...

The course of COVID-19 in patients with psoriasis was characterized and factors associated with hospitalization were identified in an international case study. The use of biologic agents among ...

Higher BMI, BMR, BSA, and weight correlate with more severe psoriasis and reduced treatment efficacy, particularly with biologic therapies. Personalized dosing strategies may be necessary for biologic ...

Please provide your email address to receive an email when new articles are posted on . Understanding drug survival is important for clinical prescribing and long-term disease control. Bimekizumab has ...

Please provide your email address to receive an email when new articles are posted on . The majority of patients and clinicians agreed with the use of as-needed biologic therapy for psoriasis.

For patients with plaque psoriasis who initiated treatment with a first-line biologic, the average treatment cost more than doubled from 2007 to 2021 as more patients started newer IL-17 and IL-23 ...

The retrospective analysis, published in the Journal of Clinical Medicine, supports the use of tildrakizumab, an interleukin-23 (IL-23) inhibitor that was FDA approved in 2018 for moderate-to-severe ...

The psoriasis market is experiencing steady growth, driven by rising disease prevalence, improved diagnosis rates, and greater patient access to advanced therapies. The shift from conventional ...

Biologics targeting interleukin-12, -23, and -17 were associated with a lower rate of serious infections among older adults with psoriatic disease. Older systemic medications, including methotrexate, ...

Topical or oral corticosteroids generally cost $10 to $20 a month.